GW’s extensive research into the pharmacology of cannabinoids continues to yield highly promising data and new intellectual property across a range of therapeutic areas. GW continues to invest in research to accelerate further growth and value creation through the development and licensing of several new cannabinoid drug candidates.
Cannabinoids exert many of their pharmacological effects by interacting with, and modulating, the human endocannabinoid system. This comprises a family of cannabinoid receptors, their endogenous activators (ligands), enzymes and transporters. There are at least two types of cannabinoid receptors, CB1 and CB2. In addition, cannabinoids interacts with other important neurotransmitter/ neuromodulatory systems as well as TRP Channels. The far-reaching pharmacology of cannabinoids explains why they hold such promise in such diverse therapeutic areas.